Formycon Reveals Keytruda Biosimilar In The Works

A Formulation Patent Is Pending While Manufacturing Capacity Has Been Secured

 
• By Rosalind Rei
  
Pembrolizumab molecule
Formycon has revealed pembrolizumab as one of its in-development biosimilars • Source: Shutterstock
Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Biosimilars

More from Products